aap without one-time effects, sales of the first half of 2009 are slightly below previous year's

Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment achieved in the first six months of the financial year 2009 - according to preliminary figures - sales of EUR 14.7 million (-10% to the first half of 2008). Both periods still contain one-time effects. In the previous year, within an initial order from a global partner, we registered orders to the amount of EUR 1.6 million. In March 2009 we were able to sell a product that does not belong anymore to the core business in the amount of EUR 0.5 million. Without the consideration of these not re-occurring revenues, the sales of the first half of 2009 decreased slightly by 3%. Within the cost reduction program, further measures were carried out in the second quarter. These measures should show first effects on the company's performance during the current financial year. For the second half of 2009, aap expects a recovery of the demand and along with the interest of global partner companies in aap's research & development projects, improvements on the sales and revenue side. The publication of the full aap Implantate AG six month report 2009 is scheduled for August 17, 2009. _______________________ aap is a medical technology company that develops, manufactures and markets biomaterials and implants for trauma and orthopaedics. Its product portfolio includes bone cements, bone graft substitutes, antibiotic carriers, and implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003. Please address any queries to: aap Implantate AG, Nanette Hüdepohl, Head of Corporate Communications, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de For further information about aap bio implants, visit www.aap-bioimplants.com --- End of Message --- aap Implantate AG Lorenzweg 5 Berlin Germany WKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;